Osteoporosis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Osteoporosis – Pipeline Review, H1 2018’, provides an overview of the Osteoporosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Osteoporosis

– The report reviews pipeline therapeutics for Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Osteoporosis therapeutics and enlists all their major and minor projects

– The report assesses Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Osteoporosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Osteoporosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abreos Biosciences Inc

Alvogen Korea Co Ltd

Amgen Inc

Asahi Kasei Corp

BiologicsMD Inc

Bone Biologics Corp

Bristol-Myers Squibb Co

Cadila Healthcare Ltd

Cellmid Ltd

ChoDang Pharm Co Ltd

Chugai Pharmaceutical Co Ltd

Corium International Inc

Daiichi Sankyo Co Ltd

Dong Wha Pharma Co Ltd

ElexoPharm GmbH

Eli Lilly and Co

EndoCeutics Inc

Entera Bio Ltd

Enteris BioPharma Inc

Enzene Biosciences Ltd

Enzo Biochem Inc

Evgen Pharma Plc

Gador SA

GL Pharm Tech Corp

GlycoNex Inc

Hanmi Pharmaceuticals Co Ltd

Haoma Medica Ltd

Huons Global Co Ltd

Immunovo BV

Immunwork Inc

Intas Pharmaceuticals Ltd

Ipsen SA

JHL Biotech Inc

Kaken Pharmaceutical Co Ltd

Lead Discovery Center GmbH

Lotus Pharmaceutical Co Ltd

Lupin Ltd

Luye Pharma Group Ltd

mAbxience SA

Merck & Co Inc

Millendo Therapeutics Inc

NIBEC

Omeros Corp

Oncobiologics Inc

Paras Biopharmaceuticals Finland Oy

Pfenex Inc

PhytoHealth Corp

R Pharm

Ribomic Inc

Richter Gedeon Nyrt

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shenzhen Salubris Pharmaceuticals Co Ltd

Shin Poong PharmCo Ltd

Sinil Pharmaceutical Co Ltd

Stelis Biopharma Pvt Ltd

Terpenoid Therapeutics Inc

TSH Biopharm Corporation Ltd

Uni-Bio Science Group Ltd

Viking Therapeutics Inc

Wroclawskie Centrum Badan EIT+ Sp z oo

Yooyoung Pharm Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Osteoporosis Overview 7

Osteoporosis Therapeutics Development 8

Osteoporosis Therapeutics Assessment 25

Osteoporosis Companies Involved in Therapeutics Development 35

Osteoporosis Drug Profiles 62

Osteoporosis Dormant Projects 220

Osteoporosis Discontinued Products 228

Osteoporosis Product Development Milestones 229

Appendix 238

List of Tables

List of Tables

Table 1: Number of Products under Development for Osteoporosis, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 7: Number of Products under Development by Universities/Institutes, H1 2018

Table 8: Products under Development by Companies, H1 2018

Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 14: Table 15Products under Development by Universities/Institutes, H1 2018

Table 16: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Table 17: Number of Products by Stage and Target, H1 2018

Table 18: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 19: Number of Products by Stage and Mechanism of Action, H1 2018

Table 20: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 21: Number of Products by Stage and Route of Administration, H1 2018

Table 22: Number of Products by Stage and Molecule Type, H1 2018

Table 23: Osteoporosis Pipeline by Abreos Biosciences Inc, H1 2018

Table 24: Osteoporosis Pipeline by Alvogen Korea Co Ltd, H1 2018

Table 25: Osteoporosis Pipeline by Amgen Inc, H1 2018

Table 26: Osteoporosis Pipeline by Asahi Kasei Corp, H1 2018

Table 27: Osteoporosis Pipeline by BiologicsMD Inc, H1 2018

Table 28: Osteoporosis Pipeline by Bone Biologics Corp, H1 2018

Table 29: Osteoporosis Pipeline by Bristol-Myers Squibb Co, H1 2018

Table 30: Osteoporosis Pipeline by Cadila Healthcare Ltd, H1 2018

Table 31: Osteoporosis Pipeline by Cellmid Ltd, H1 2018

Table 32: Osteoporosis Pipeline by ChoDang Pharm Co Ltd, H1 2018

Table 33: Osteoporosis Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Table 34: Osteoporosis Pipeline by Corium International Inc, H1 2018

Table 35: Osteoporosis Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Table 36: Osteoporosis Pipeline by Dong Wha Pharma Co Ltd, H1 2018

Table 37: Osteoporosis Pipeline by ElexoPharm GmbH, H1 2018

Table 38: Osteoporosis Pipeline by Eli Lilly and Co, H1 2018

Table 39: Osteoporosis Pipeline by EndoCeutics Inc, H1 2018

Table 40: Osteoporosis Pipeline by Entera Bio Ltd, H1 2018

Table 41: Osteoporosis Pipeline by Enteris BioPharma Inc, H1 2018

Table 42: Osteoporosis Pipeline by Enzene Biosciences Ltd, H1 2018

Table 43: Osteoporosis Pipeline by Enzo Biochem Inc, H1 2018

Table 44: Osteoporosis Pipeline by Evgen Pharma Plc, H1 2018

Table 45: Osteoporosis Pipeline by Gador SA, H1 2018

Table 46: Osteoporosis Pipeline by GL Pharm Tech Corp, H1 2018

Table 47: Osteoporosis Pipeline by GlycoNex Inc, H1 2018

Table 48: Osteoporosis Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Table 49: Osteoporosis Pipeline by Haoma Medica Ltd, H1 2018

Table 50: Osteoporosis Pipeline by Huons Global Co Ltd, H1 2018

Table 51: Osteoporosis Pipeline by Immunovo BV, H1 2018

Table 52: Osteoporosis Pipeline by Immunwork Inc, H1 2018

Table 53: Osteoporosis Pipeline by Intas Pharmaceuticals Ltd, H1 2018

Table 54: Osteoporosis Pipeline by Ipsen SA, H1 2018

Table 55: Osteoporosis Pipeline by JHL Biotech Inc, H1 2018

Table 56: Osteoporosis Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018

Table 57: Osteoporosis Pipeline by Lead Discovery Center GmbH, H1 2018

Table 58: Osteoporosis Pipeline by Lotus Pharmaceutical Co Ltd, H1 2018

Table 59: Osteoporosis Pipeline by Lupin Ltd, H1 2018

Table 60: Osteoporosis Pipeline by Luye Pharma Group Ltd, H1 2018

Table 61: Osteoporosis Pipeline by mAbxience SA, H1 2018

Table 62: Osteoporosis Pipeline by Merck & Co Inc, H1 2018

Table 63: Osteoporosis Pipeline by Millendo Therapeutics Inc, H1 2018

Table 64: Osteoporosis Pipeline by NIBEC, H1 2018

Table 65: Osteoporosis Pipeline by Omeros Corp, H1 2018

Table 66: Osteoporosis Pipeline by Oncobiologics Inc, H1 2018

Table 67: Osteoporosis Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018

Table 68: Osteoporosis Pipeline by Pfenex Inc, H1 2018

Table 69: Osteoporosis Pipeline by PhytoHealth Corp, H1 2018

Table 70: Osteoporosis Pipeline by R Pharm, H1 2018

Table 71: Osteoporosis Pipeline by Ribomic Inc, H1 2018

Table 72: Osteoporosis Pipeline by Richter Gedeon Nyrt, H1 2018

Table 73: Osteoporosis Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018

Table 74: Osteoporosis Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2018

Table 75: Osteoporosis Pipeline by Shin Poong PharmCo Ltd, H1 2018

Table 76: Osteoporosis Pipeline by Sinil Pharmaceutical Co Ltd, H1 2018

Table 77: Osteoporosis Pipeline by Stelis Biopharma Pvt Ltd, H1 2018

Table 78: Osteoporosis Pipeline by Terpenoid Therapeutics Inc, H1 2018

Table 79: Osteoporosis Pipeline by TSH Biopharm Corporation Ltd, H1 2018

Table 80: Osteoporosis Pipeline by Uni-Bio Science Group Ltd, H1 2018

Table 81: Osteoporosis Pipeline by Viking Therapeutics Inc, H1 2018

Table 82: Osteoporosis Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2018

Table 83: Osteoporosis Pipeline by Yooyoung Pharm Co Ltd, H1 2018

Table 84: Osteoporosis Dormant Projects, H1 2018

Table 85: Osteoporosis Dormant Projects, H1 2018 (Contd..1), H1 2018

Table 86: Osteoporosis Dormant Projects, H1 2018 (Contd..2), H1 2018

Table 87: Osteoporosis Dormant Projects, H1 2018 (Contd..3), H1 2018

Table 88: Osteoporosis Dormant Projects, H1 2018 (Contd..4), H1 2018

Table 89: Osteoporosis Dormant Projects, H1 2018 (Contd..5), H1 2018

Table 90: Osteoporosis Dormant Projects, H1 2018 (Contd..6), H1 2018

Table 91: Osteoporosis Dormant Projects, H1 2018 (Contd..7), H1 2018

Table 92: Osteoporosis Discontinued Products, H1 2018

List of Figures

List of Figures

Figure 1: Number of Products under Development for Osteoporosis, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Mechanism of Actions, H1 2018

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports